Takeru Wakatsuki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takeru Wakatsuki has a total of 184 co-authors. Here are the top co-authors by number of shared publications:
- Kensei Yamaguchi
Gastroenterological Chemotherapy Department, The Cancer Institute Hospital of JFCR, Tokyo, Japan
50 shared publications - Hiroyuki Seimiya
Division of Molecular Biotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Koto-ku, Japan
37 shared publications - Tetsuo Mashima
Division of Molecular Biotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Koto-ku, Japan
36 shared publications - Ayane Nakamura
Division of Molecular Biotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan
35 shared publications - Jin Lee
Division of Molecular Biotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan
35 shared publications - Kengo Takeuchi
Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
35 shared publications
Latest Publications
- Open Access
- 27 May 2026
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 31 (7) , 1245-1257
High-dose dexamethasone and prolonged infusion time prevent oxaliplatin-related hypersensitivity reactions in patients with metastatic colorectal cancer
Background: Oxaliplatin (OXA), a key cytotoxic agent used in the treatment of gastrointestinal cancers, is frequently discontinued due to hypersensitivity reactions (HSRs). We developed a protocol to mitigate HSRs and assessed its clinical efficacy. Methods: We retrospectively analyzed HSRs in patients with metastatic colorectal cancer (mCRC) who were treated with OXA-containing regimens between 2005 and 2019. We evaluated the clinical utility of our HSR prevention protocol in patients who experienced grade 1–3 HSRs following OXA-based chemotherapy. The protocol involved increasing dexamethasone to 16.5 mg/body and extending the OXA infusion time from 2 to 4 h. Results: Among 205 patients, 105 (51.2%) experienced grade 1, 95 (46.3%) grade 2, and 5 (2.4%) grade 3 HSRs. Most patients (87.8%) received either the FOLFOX4 or modified FOLFOX6 regimen. Patients underwent a median of 11 OXA cycles before their initial HSR. OXA was successfully reintroduced in 108 patients (52.7%) using the HSR prevention protocol. The median OXA-free interval was 23 days and the median progression-free survival after reintroduction was 6.4 months (95% confidence interval [CI]: 4.6–8.2). Reasons for discontinuation included a second HSR in 97 patients (47.3%), disease progression in 74 (36.1%), and chemotherapy-induced peripheral neuropathy (CIPN) in 15 (7.3%). Forty-six patients (22.4%) experienced an HSR during the initial prevention protocol. Only six patients (2.9%) experienced grade 3 HSRs and no grade 4 or 5 events were observed. Conclusion: High-dose dexamethasone and prolonged infusion time may enable OXA reintroduction, providing an alternative to permanent discontinuation in mCRC patients with prior HSRs. Registry number: 2024-GB-073 (retrospectively registered).
- 27 May 2026
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 31 (7) , 1245-1257
Open AccessHigh-dose dexamethasone and prolonged infusion time prevent oxaliplatin-related hypersensitivity reactions in patients with metastatic colorectal cancer
Background: Oxaliplatin (OXA), a key cytotoxic agent used in the treatment of gastrointestinal cancers, is frequently discontinued due to hypersensitivity reactions (HSRs). We developed a protocol to mitigate HSRs and assessed its clinical efficacy. Methods: We retrospectively analyzed HSRs in patients with metastatic colorectal cancer (mCRC) who were treated with OXA-containing regimens between 2005 and 2019. We evaluated the clinical utility of our HSR prevention protocol in patients who experienced grade 1–3 HSRs following OXA-based chemotherapy. The protocol involved increasing dexamethasone to 16.5 mg/body and extending the OXA infusion time from 2 to 4 h. Results: Among 205 patients, 105 (51.2%) experienced grade 1, 95 (46.3%) grade 2, and 5 (2.4%) grade 3 HSRs. Most patients (87.8%) received either the FOLFOX4 or modified FOLFOX6 regimen. Patients underwent a median of 11 OXA cycles before their initial HSR. OXA was successfully reintroduced in 108 patients (52.7%) using the HSR prevention protocol. The median OXA-free interval was 23 days and the median progression-free survival after reintroduction was 6.4 months (95% confidence interval [CI]: 4.6–8.2). Reasons for discontinuation included a second HSR in 97 patients (47.3%), disease progression in 74 (36.1%), and chemotherapy-induced peripheral neuropathy (CIPN) in 15 (7.3%). Forty-six patients (22.4%) experienced an HSR during the initial prevention protocol. Only six patients (2.9%) experienced grade 3 HSRs and no grade 4 or 5 events were observed. Conclusion: High-dose dexamethasone and prolonged infusion time may enable OXA reintroduction, providing an alternative to permanent discontinuation in mCRC patients with prior HSRs. Registry number: 2024-GB-073 (retrospectively registered).
- Open Access
- 2 April 2026
- Published by Springer Nature in Gastric Cancer
- Vol. 29 (3) , 597-610
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab deruxtecan efficacy in patients with HER2-positive gastric cancer
Background Intratumoral HER2 heterogeneity has been associated with poor response to trastuzumab-based chemotherapy in HER2-positive gastric cancer. However, its clinical significance in patients treated with trastuzumab deruxtecan (T-DXd) remains unclear. Methods Patients with advanced HER2-positive gastric cancer who received T-DXd as second-line or later therapy were enrolled. HER2-positive proportion was defined as the percentage of tumor cells with immunohistochemical score ≥ 2 + in diagnostic specimens obtained before first-line therapy. The cutoff value was determined using time-dependent receiver operating characteristic analysis. Results Forty-three patients were enrolled. Median progression-free survival (PFS) and overall survival (OS) were 4.7 and 8.1 months, respectively. With an optimal cutoff of 79%, 20 patients (47%) were in the HER2-homogeneity group and 23 (53%) in the HER2-heterogeneity group. The HER2-homogeneity group showed significantly longer PFS (6.3 vs. 3.1 months, p = 0.002) and OS (9.8 vs. 6.0 months, p = 0.006) with higher overall response rate (79% vs. 19%, p < 0.001). In Cox proportional hazards model, HER2-homogeneity was an independent prognostic factor for both PFS (hazard ratio (HR) 0.37, 95% confidence interval (CI) 0.18–0.76, p = 0.007) and OS (HR 0.41, 95% CI 0.21–0.82, p = 0.01). Conclusions Intratumoral HER2 heterogeneity in pre-treatment diagnostic specimens was associated with T-DXd efficacy and may represent a potential prognostic factor.
- 2 April 2026
- Published by Springer Nature in Gastric Cancer
- Vol. 29 (3) , 597-610
Open AccessClinical impact of intratumoral HER2 heterogeneity on trastuzumab deruxtecan efficacy in patients with HER2-positive gastric cancer
Background Intratumoral HER2 heterogeneity has been associated with poor response to trastuzumab-based chemotherapy in HER2-positive gastric cancer. However, its clinical significance in patients treated with trastuzumab deruxtecan (T-DXd) remains unclear. Methods Patients with advanced HER2-positive gastric cancer who received T-DXd as second-line or later therapy were enrolled. HER2-positive proportion was defined as the percentage of tumor cells with immunohistochemical score ≥ 2 + in diagnostic specimens obtained before first-line therapy. The cutoff value was determined using time-dependent receiver operating characteristic analysis. Results Forty-three patients were enrolled. Median progression-free survival (PFS) and overall survival (OS) were 4.7 and 8.1 months, respectively. With an optimal cutoff of 79%, 20 patients (47%) were in the HER2-homogeneity group and 23 (53%) in the HER2-heterogeneity group. The HER2-homogeneity group showed significantly longer PFS (6.3 vs. 3.1 months, p = 0.002) and OS (9.8 vs. 6.0 months, p = 0.006) with higher overall response rate (79% vs. 19%, p < 0.001). In Cox proportional hazards model, HER2-homogeneity was an independent prognostic factor for both PFS (hazard ratio (HR) 0.37, 95% confidence interval (CI) 0.18–0.76, p = 0.007) and OS (HR 0.41, 95% CI 0.21–0.82, p = 0.01). Conclusions Intratumoral HER2 heterogeneity in pre-treatment diagnostic specimens was associated with T-DXd efficacy and may represent a potential prognostic factor.
- Open Access
- 15 March 2026
- Published by Springer Nature in Targeted Oncology
- Vol. 21 (2) , 269-283
Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer
Background While oncogene co-amplification is frequently observed, its clinical significance remains unclear, particularly with regard to its association with copy number. Objective The aim of this study was to elucidate the molecular traits of human epidermal growth factor receptor 2 (HER2)-positive gastric cancer, focusing on copy numbers of ERBB2 and other oncogenes, and to investigate their association with treatment efficacy. Methods This is a collaborative study associated with the HIGHSOX trial investigating the efficacy of trastuzumab combined with S-1 and oxaliplatin in HER2-positive gastric cancer, and next-generation sequencing was performed. Tumors in which ERBB2 was the highest copy number among co-amplified oncogenes were defined as “ERBB2 dominant”. The others were defined as “non-ERBB2 dominant”. Results A total of 32 patients were enrolled, and the median progression-free survival and overall survival were 11.8 and 28.8 months, respectively. ERBB2 amplification was present in 84.4%, with the majority (88%) exhibiting either co-amplification of ERBB2 with other oncogenes (75%) or amplification of other oncogenes alone (13%), including KRAS, MET, FGFR2, and CCNE1. A potential inverse relationship in copy number between ERBB2 and other oncogenes (ρ = − 0.345, p = 0.058) was observed. The ERBB2 copy number was significantly higher than that of other oncogenes in ERBB2-dominant tumors, whereas the opposite pattern was observed in non-ERBB2-dominant tumors (both p < 0.001). Non-ERBB2-dominant tumors showed significantly shorter progression-free survival (median progression-free survival: 6.9 vs 17.0 months, hazard ratio, 6.40, p = 0.001), overall survival (median overall survival 14.8 vs 35.5 months, hazard ratio, 2.72, p = 0.016), and a numerically lower response rate (63.6% vs 90.0%, p = 0.151). Conclusions Copy number-based oncogene dominance may suggest tumor dependence and response to HER2-targeted therapy, highlighting a potential novel biomarker in HER2-positive gastric cancer.
- 15 March 2026
- Published by Springer Nature in Targeted Oncology
- Vol. 21 (2) , 269-283
Open AccessCopy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer
Background While oncogene co-amplification is frequently observed, its clinical significance remains unclear, particularly with regard to its association with copy number. Objective The aim of this study was to elucidate the molecular traits of human epidermal growth factor receptor 2 (HER2)-positive gastric cancer, focusing on copy numbers of ERBB2 and other oncogenes, and to investigate their association with treatment efficacy. Methods This is a collaborative study associated with the HIGHSOX trial investigating the efficacy of trastuzumab combined with S-1 and oxaliplatin in HER2-positive gastric cancer, and next-generation sequencing was performed. Tumors in which ERBB2 was the highest copy number among co-amplified oncogenes were defined as “ERBB2 dominant”. The others were defined as “non-ERBB2 dominant”. Results A total of 32 patients were enrolled, and the median progression-free survival and overall survival were 11.8 and 28.8 months, respectively. ERBB2 amplification was present in 84.4%, with the majority (88%) exhibiting either co-amplification of ERBB2 with other oncogenes (75%) or amplification of other oncogenes alone (13%), including KRAS, MET, FGFR2, and CCNE1. A potential inverse relationship in copy number between ERBB2 and other oncogenes (ρ = − 0.345, p = 0.058) was observed. The ERBB2 copy number was significantly higher than that of other oncogenes in ERBB2-dominant tumors, whereas the opposite pattern was observed in non-ERBB2-dominant tumors (both p < 0.001). Non-ERBB2-dominant tumors showed significantly shorter progression-free survival (median progression-free survival: 6.9 vs 17.0 months, hazard ratio, 6.40, p = 0.001), overall survival (median overall survival 14.8 vs 35.5 months, hazard ratio, 2.72, p = 0.016), and a numerically lower response rate (63.6% vs 90.0%, p = 0.151). Conclusions Copy number-based oncogene dominance may suggest tumor dependence and response to HER2-targeted therapy, highlighting a potential novel biomarker in HER2-positive gastric cancer.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
Relationship between proteomic and ELISA data (related to Figure 1)
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
Relationship between proteomic and ELISA data (related to Figure 1)
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
Blocking ANGPTL3 synergistically enhances anti-PD1 therapeutic efficacy in mouse tumor models. BALB/c mice were subcutaneously (5 × 105) implanted with Colon26 cells, and received intraperitoneal injection of anti-ANGPTL3 mAb, anti-PD1 mAb, or mIgG as a control at 10 mg/kg on days 3 and 10 after tumor implantation (n = 5). On day 17, the subcutaneous tumor and spleen were harvested randomly from three of 10 mice for assays. A, Suppression of tumor growth by treatments (n = 10). Open circles, mIgG control; closed circles, anti-ANGPTL3 mAb; and closed triangles, anti-PD1 mAb. Gray diamonds, anti-ANGPTL3 mAb and anti-PD1 mAb. B, Dramatical increase of tumor-infiltrating lymphocytes (TIL) by anti-ANGPTL3/-PD1 combination therapy. Tumor-infiltrating lymphocytes were analyzed by flow cytometry (n = 3). C, Increase of SPCs by treatments. SPCs were analyzed by flow cytometry (n = 3). D, Enhancement of the cytotoxic activity of splenic CD8+ T cells by anti-ANGPTL3/-PD1 combination therapy. AH1-prestimulated CD8+ T cells were cocultured with Colon26 cells as a target at effector:target (E:T) ratio = 40:1 for 4 hours (n = 3). Splenic DX5+ NK cells were also cocultured with Yac1 cells as a target at E:T ratio = 20:1 for 4 hours (n = 3). Graphs show means ± SDs. **, P < 0.05 vs. mIgG control analyzed by the Mann–Whitney U test, two-way ANOVA, or one-way ANOVA. Representative data of an experiment of three independent experiments with consistent results. aANGPTL3, anti-ANGPTL3; aPD1, anti-PD1.
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
Blocking ANGPTL3 synergistically enhances anti-PD1 therapeutic efficacy in mouse tumor models. BALB/c mice were subcutaneously (5 × 105) implanted with Colon26 cells, and received intraperitoneal injection of anti-ANGPTL3 mAb, anti-PD1 mAb, or mIgG as a control at 10 mg/kg on days 3 and 10 after tumor implantation (n = 5). On day 17, the subcutaneous tumor and spleen were harvested randomly from three of 10 mice for assays. A, Suppression of tumor growth by treatments (n = 10). Open circles, mIgG control; closed circles, anti-ANGPTL3 mAb; and closed triangles, anti-PD1 mAb. Gray diamonds, anti-ANGPTL3 mAb and anti-PD1 mAb. B, Dramatical increase of tumor-infiltrating lymphocytes (TIL) by anti-ANGPTL3/-PD1 combination therapy. Tumor-infiltrating lymphocytes were analyzed by flow cytometry (n = 3). C, Increase of SPCs by treatments. SPCs were analyzed by flow cytometry (n = 3). D, Enhancement of the cytotoxic activity of splenic CD8+ T cells by anti-ANGPTL3/-PD1 combination therapy. AH1-prestimulated CD8+ T cells were cocultured with Colon26 cells as a target at effector:target (E:T) ratio = 40:1 for 4 hours (n = 3). Splenic DX5+ NK cells were also cocultured with Yac1 cells as a target at E:T ratio = 20:1 for 4 hours (n = 3). Graphs show means ± SDs. **, P < 0.05 vs. mIgG control analyzed by the Mann–Whitney U test, two-way ANOVA, or one-way ANOVA. Representative data of an experiment of three independent experiments with consistent results. aANGPTL3, anti-ANGPTL3; aPD1, anti-PD1.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
ANGPTL3 levels are high in the peripheral blood of patients with AGC who progress after nivolumab treatment. Peripheral blood was collected from patients with AGC before and 1 month after initiating nivolumab therapy, and ANGPTL3 levels in plasma were measured by proteomic profiling or ELISA (n = 80). A, ANGPTL3 seq.10382-1 detected by proteomic profiling. B, ANGPTL3 seq.10391-1 detected by proteomic profiling. C, ANGPTL3 protein detected by ELISA. The median values for each group are shown in brackets. No significant differences were observed between pretreatment and posttreatment levels for any of the markers.
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
ANGPTL3 levels are high in the peripheral blood of patients with AGC who progress after nivolumab treatment. Peripheral blood was collected from patients with AGC before and 1 month after initiating nivolumab therapy, and ANGPTL3 levels in plasma were measured by proteomic profiling or ELISA (n = 80). A, ANGPTL3 seq.10382-1 detected by proteomic profiling. B, ANGPTL3 seq.10391-1 detected by proteomic profiling. C, ANGPTL3 protein detected by ELISA. The median values for each group are shown in brackets. No significant differences were observed between pretreatment and posttreatment levels for any of the markers.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
Summary of PFS and OS of the two groups divided by the cutoff values of ANGPTL3.
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
Summary of PFS and OS of the two groups divided by the cutoff values of ANGPTL3.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
ANGPTL3 data by ELISA (related to Figure 4)
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
ANGPTL3 data by ELISA (related to Figure 4)
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
High posttreatment ANGPTL3 levels are significantly associated with shorter OS of patients with AGC after nivolumab treatment. Patients were divided into two groups, high (red lines) and low (blue lines), based on ANGPTL3 cutoff values after treatment, and significant differences in PFS and OS were statistically analyzed by the Kaplan–Meier method and the Mantel–Cox log-rank test. A, ANGPTL3 seq.10382-1 detected by proteomic profiling. B, ANGPTL3 seq.10391-1 detected by proteomic profiling. C, ANGPTL3 protein detected by ELISA.
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
High posttreatment ANGPTL3 levels are significantly associated with shorter OS of patients with AGC after nivolumab treatment. Patients were divided into two groups, high (red lines) and low (blue lines), based on ANGPTL3 cutoff values after treatment, and significant differences in PFS and OS were statistically analyzed by the Kaplan–Meier method and the Mantel–Cox log-rank test. A, ANGPTL3 seq.10382-1 detected by proteomic profiling. B, ANGPTL3 seq.10391-1 detected by proteomic profiling. C, ANGPTL3 protein detected by ELISA.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Data from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
Anti-PD1/-PDL1 therapy has attracted great attention in cancer therapy in recent years, but a serious problem remains that only a small portion of patients can benefit from it. In this study, we attempted to identify a molecule that is associated with anti-PD1/-PDL1 therapeutic efficacy through proteomic profiling of plasma obtained from patients with advanced gastric cancer (AGC) receiving anti-PD1 nivolumab monotherapy. We collected peripheral blood from 91 patients with AGC before and after nivolumab treatment, and plasma was analyzed by the SomaScan v4.1 and ELISA. Relationships between the levels and patient prognosis were statistically analyzed. To evaluate antitumor effects induced by blocking the identified molecule for which high levels were significantly associated with poor prognosis, in vivo therapeutic experiments using mouse tumor models were conducted. Proteomic data revealed that the levels of 14 molecules both before and after treatment were significantly higher in patients with progressive disease (PD) than those in non-PD patients. Among them, angiopoietin-like 3 (ANGPTL3) levels were notably higher in PD patients than those in non-PD patients, and patients with high levels of ANGPTL3 either before or after treatment showed significantly worse prognosis. In mouse tumor models with increased ANGPTL3, anti-ANGPTL3 therapy significantly reduced tumor growth and synergistically enhanced anti-PD1 therapeutic efficacy. These suggest that high levels of ANGPTL3 in plasma are a significant risk factor associated with unresponsiveness to anti-PD1 treatment and poor prognosis. Targeting ANGPTL3 in the peripheral circulation may be a promising strategy to improve clinical outcomes in anti-PD1/-PDL1 therapy for AGC.Significance:This study provides valuable evidence suggesting the importance of targeting peripheral ANGPTL3 in the anti-PD1/-PDL1 therapy for AGC and will encourage and accelerate the development of a useful biomarker to predict responders/nonresponders to the therapy, leading to improved clinical outcomes in the treatment of gastric cancer.
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
Anti-PD1/-PDL1 therapy has attracted great attention in cancer therapy in recent years, but a serious problem remains that only a small portion of patients can benefit from it. In this study, we attempted to identify a molecule that is associated with anti-PD1/-PDL1 therapeutic efficacy through proteomic profiling of plasma obtained from patients with advanced gastric cancer (AGC) receiving anti-PD1 nivolumab monotherapy. We collected peripheral blood from 91 patients with AGC before and after nivolumab treatment, and plasma was analyzed by the SomaScan v4.1 and ELISA. Relationships between the levels and patient prognosis were statistically analyzed. To evaluate antitumor effects induced by blocking the identified molecule for which high levels were significantly associated with poor prognosis, in vivo therapeutic experiments using mouse tumor models were conducted. Proteomic data revealed that the levels of 14 molecules both before and after treatment were significantly higher in patients with progressive disease (PD) than those in non-PD patients. Among them, angiopoietin-like 3 (ANGPTL3) levels were notably higher in PD patients than those in non-PD patients, and patients with high levels of ANGPTL3 either before or after treatment showed significantly worse prognosis. In mouse tumor models with increased ANGPTL3, anti-ANGPTL3 therapy significantly reduced tumor growth and synergistically enhanced anti-PD1 therapeutic efficacy. These suggest that high levels of ANGPTL3 in plasma are a significant risk factor associated with unresponsiveness to anti-PD1 treatment and poor prognosis. Targeting ANGPTL3 in the peripheral circulation may be a promising strategy to improve clinical outcomes in anti-PD1/-PDL1 therapy for AGC.Significance:This study provides valuable evidence suggesting the importance of targeting peripheral ANGPTL3 in the anti-PD1/-PDL1 therapy for AGC and will encourage and accelerate the development of a useful biomarker to predict responders/nonresponders to the therapy, leading to improved clinical outcomes in the treatment of gastric cancer.